Iclaprim

Drug Profile

Iclaprim

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Nosocomial infections
  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • Suspended Nosocomial pneumonia
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 06 Oct 2017 Antimicrobial and Pharmacodynamics data from preclinical studies in Methicillin-resistant Staphylococcus aureus infections presented at the IDWeek 2017
  • 04 Oct 2017 Motif Bio announces intention to submit NDA for iclaprim in Skin-and-soft-tissue-infections by the end of 1Q 2018
  • 04 Oct 2017 Positive topline efficacy and adverse events data from the phase III REVIVE-2 trial in Skin and soft tissue infections released by Motif Bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top